CBG (cannabigerol) is a cannabinoid found in cannabis that isn’t as well-known as some of the other mainstream ones. It is found to be in under 1% of marijuana strains and is considered to be minor. Many growers are trying to manipulate the genetics of the marijuana they are growing to produce higher yields of CBG. One grower called Subcool Seeds is doing some cross-breeding with multiple strains to get that higher content of CBG.
If scientists can pinpoint the exact extraction time of CBG, they can get higher levels of it from plants that are budding. Despite being a minor cannabinoid, CBG has still shown to have medicinal and therapeutic benefits. It is known to be effective in treating people with glaucoma becasue it is said to reduce the amount of intraocular pressure in the eyes. Its vasodilating effects and neuroprotectivity can benefit patients. CBG was found to be an effective tactic in lowering the inflammation on experimentalt mice with inflammatory bowerl disease.
One study in 2015 revealed that CBG could protect neurons in mice that had Huntington’s disease. Because Huntington’s disease is characterized by nerve cell degeneration, this means CBG could help halt that degeneration in the nerves. CBG has been shown to lower the chance that cancer will spread by blocking the receptors that cause it to spread in the first place. One study showed positive results in the ability to stop the growth of colorectal cancer cells in mice.
It stopped tumors from growing and the uses of it in the future for colorectal cancer is promising. One particular study tested the effects of five various cannabinoids on bladder contractions. Overall, CBG was found to do the best job at lowering or stopping the muscle contractions, so future use of it in disorders involving bladder function may prove to hold some value.